A Phase 3 interventional study of human autologous synovial stem cells in Meniscus Injury, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Active, not recruiting at 4 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-02.
Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
A single-arm, multi-center study to verify that knee joint function at 52 weeks after injection of FF-31501 is better than at screening in patients with meniscus tear who are eligible for meniscectomy .
FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with one or more of the following symptoms
Exclusion Criteria:
Patients with the following complications and poor general condition
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: human autologous synovial stem cells
A single injection of 1.5 to 9.0 x 10\^7 human autologous synovial stem cells under arthroscopy
Lysholm score
It consists of items that measure: pain, instability, locking, swelling, limp, stair climbing, squatting, and need for support. Lowest and highest scores are 0 and 100 (better), respectively.
Time frame: Screening up to 52 weeks
Arthroscopic assessment of the meniscus
The structure and function of the repaired meniscus will be assessed in terms of the presence, stability, and smoothness of the meniscus by arthroscopic imaging and MRI.
Time frame: Meniscus repair up to 52 weeks
Knee injury and osteoarthritis outcome score (KOOS)
The KOOS consists of five subscales; Pain, other symptoms, function in daily living (ADL), function in sport and recreation (Sport/Rec) and knee related quality of life (QOL). Lowest and highest scores are 0 and 100 (better), respectively.
Time frame: Screening up to the Day before injection,4,12,24 and 52 weeks
Numerical Rating Scale (NRS)
NRS consists of an 11-point scale to evaluate current knee pain where no pain is indicated by '0', and the worst pain imaginable by '10'.
Time frame: Screening up to the Day before injection,4,12,24 and 52 weeks
Kellgren Lawrence
The Kellgren and Lawrence system is a common method of classifying the severity of osteoarthritis (OA) using five grades.
Time frame: Screening up to 24 and 52 weeks
Started Jan 2023 (actual). Primary completion is estimated for Dec 2024, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
FUJIFILM Toyama Chemical Co., Ltd.